Piper Sandler Maintains Overweight on Biohaven, Raises Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Biohaven (NYSE:BHVN) and raised the price target from $66 to $76.
September 23, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has increased its price target for Biohaven from $66 to $76, maintaining an Overweight rating. This suggests a positive outlook for the stock.
The increase in price target from $66 to $76 by Piper Sandler, along with maintaining an Overweight rating, indicates a positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100